Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G, Relli V, Deserti M, Palloni A, Indio V, Astolfi A, Serravalle S, Mattiaccio A, Vasuri F, Malvi D, Deiana C, Pantaleo MA, Cescon M, Rizzo A, Katoh M, Tavolari S.
Brandi G, et al.
Sci Rep. 2024 Feb 7;14(1):3136. doi: 10.1038/s41598-024-52991-8.
Sci Rep. 2024.
PMID: 38326380
Free PMC article.